---
title: "Bal Pharma Ltd (BALPHARMA) — Share Price, Financials & Analysis"
symbol: "BALPHARMA"
company: "Bal Pharma Ltd"
canonical: "https://tapetide.com/stocks/BALPHARMA"
isin: "INE083D01012"
nse_symbol: "BALPHARMA"
bse_code: "524824"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 175.62
generated_at: "2026-09-13T18:47:01.727Z"
---

# Bal Pharma Ltd (BALPHARMA)

Canonical page: https://tapetide.com/stocks/BALPHARMA

## Company

- **NSE Symbol:** BALPHARMA
- **BSE Code:** 524824
- **ISIN:** INE083D01012
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2006-05-08
- **CEO:** Mr. Shailesh Dheerajmal Siroya
- **Employees:** 986
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** balpharma.com

## About

Incorporated in 1987, Bal Pharma Ltd does manufacturing and selling of pharmaceutical products and related services[1]

## Latest Price

- **Price:** ₹107.42
- **Change:** +1.21 (+1.14%)
- **Open:** ₹105.6
- **Day High:** ₹114.95
- **Day Low:** ₹104.13
- **Previous Close:** ₹106.21
- **Volume:** 316936
- **As Of:** 2026-09-11T10:22:26+00:00

## Key Fundamentals

Observed at 2026-09-11T04:53:05.784913Z.

- **Market Cap:** ₹175.62 Cr
- **Classification:** Microcap
- **P/E (reported):** 23.4
- **P/E (TTM):** 23.77
- **EPS (TTM):** ₹4.52
- **Book Value:** ₹51.65
- **Price to Book:** 2.06
- **Dividend Yield:** 1.13%
- **ROE:** 9.35%
- **ROCE:** 18.93%
- **Debt to Equity:** 1.95
- **Revenue (yearly):** ₹311.66 Cr
- **Net Income:** ₹5.93 Cr
- **EBITDA:** ₹31.9 Cr
- **52-Week High:** ₹124.6
- **52-Week Low:** ₹60
- **RSI (14):** 69.27

## Tapetide Score

- **Score:** 57 / 100
- **Score date:** 2026-09-04
- **Archetype:** Average Quality, Undemanding Price
- **What it means:** The financials sit mid-range rather than strong, and the multiple is not demanding. Nothing here stands out in either direction, so the read comes down to which single pillar you weight most and whether the next results move it off the middle.
- **Pillar profile:** Quality: Average · Valuation: Cheap · Momentum: Rising
- **Percentile:** 77.8 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 21.14 | 9% |
| growth | 57.38 | 9% |
| momentum | 81.23 | 12% |
| ownership | 50.21 | 24% |
| quality | 58.35 | 22% |
| valuation | 67.5 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company has been maintaining a healthy dividend payout of 27.5%

### Weaknesses

- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 4.46% over past five years.
- Tax rate seems low
- Company has a low return on equity of 9.37% over last 3 years.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | -10.92% | — | -9.04% |
| ebitda margin growth | -18.45% | -2.21% | 3.56% | 1.7% |
| net income growth | -69.44% | -17.64% | 35% | 6% |
| revenue growth | 6.32% | 2.08% | 1% | 4% |
| roce | -22.94% | -6.05% | 16.06% | 18.88% |
| roe | -68.33% | -9.66% | 7.94% | 5.89% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 92.54 | 81.66 | 94.63 | 74.36 | 73.69 | 73.15 | 81.88 | 65.87 | 74.02 | 87.69 | 84.08 | 88.62 |
| Expenses | 84.84 | 73.87 | 85.03 | 67.89 | 66 | 65.4 | 74.24 | 59.81 | 68.29 | 78.15 | 73.5 | 80.67 |
| Operating Profit | 7.7 | 7.79 | 9.6 | 6.47 | 7.69 | 7.75 | 7.64 | 6.06 | 5.73 | 9.54 | 10.58 | 7.95 |
| OPM % | 8.32 | 9.54 | 10.14 | 8.7 | 10.44 | 10.59 | 9.33 | 9.2 | 7.74 | 10.88 | 12.58 | 8.97 |
| Other Income | 0.14 | 0.1 | 2.45 | 0.82 | -0.2 | 0.51 | 1.08 | 0.72 | 1.12 | 0.33 | -0.24 | 0.44 |
| Interest | 3.82 | 3.66 | 4.14 | 4.24 | 3.65 | 5.01 | 3.95 | 4.05 | 3.86 | 4.85 | 4.06 | 4.47 |
| Depreciation | 2.42 | 2.96 | 2.16 | 2.43 | 2.48 | 2.69 | 2.18 | 2.52 | 2.27 | 3.23 | 3.06 | 2.78 |
| Profit before tax | 1.6 | 1.27 | 5.75 | 0.62 | 1.36 | 0.56 | 2.59 | 0.21 | 0.72 | 1.79 | 3.22 | 1.14 |
| Tax % | 39.38 | 33.07 | 3.65 | 58.06 | 23.53 | 7.14 | -108.88 | 0 | 0 | 0 | -12.11 | 0 |
| Net Profit | 0.97 | 0.85 | 5.53 | 0.26 | 1.04 | 0.52 | 5.41 | 0.21 | 0.72 | 1.79 | 3.6 | 1.13 |
| EPS in Rs | 0.61 | 0.56 | 3.46 | 0.16 | 0.65 | 0.3 | 3.41 | 0.13 | 0.45 | 1.12 | 2.25 | 0.7 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 211 | 225 | 171 | 251 | 281 | 304 | 339 | 303 | 312 | 334 |
| Expenses | 194 | 207 | 166 | 226 | 257 | 279 | 308 | 273 | 280 | 301 |
| Operating Profit | 17 | 18 | 5 | 25 | 24 | 25 | 31 | 30 | 32 | 34 |
| OPM % | 8 | 8 | 2.9 | 10 | 9 | 8 | 9 | 10 | 10 | 10 |
| Other Income | 2 | 1 | 2 | 1 | 5 | 1 | 3 | 2 | 2 | 2 |
| Interest | 9 | 13 | 13 | 12 | 11 | 12 | 15 | 17 | 17 | 17 |
| Depreciation | 7 | 6 | 8 | 10 | 9 | 9 | 10 | 10 | 11 | 11 |
| Profit before tax | 3 | 0 | -14 | 4 | 9 | 5 | 9 | 5 | 6 | 7 |
| Tax % | 87 | -1175 | -5 | -15 | 38 | 45 | 18 | -41 | -7 | — |
| Net Profit | 0 | 2 | -13 | 5 | 6 | 3 | 7 | 7 | 6 | 7 |
| EPS in Rs | 1.96 | 2.67 | -8.62 | 3.2 | 3.78 | 1.64 | 4.68 | 4.53 | 3.94 | 4.52 |
| Dividend Payout % | 51 | 37 | 0 | 31 | 26 | 61 | 26 | 26 | 30 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 14 | 14 | 14 | 14 | 15 | 15 | 16 | 16 | 16 | 16 |
| Reserves | 48 | 51 | 52 | 38 | 39 | 44 | 48 | 56 | 62 | 66 |
| Borrowings | 93 | 110 | 124 | 118 | 110 | 104 | 131 | 140 | 150 | 160 |
| Other Liabilities | 78 | 86 | 71 | 68 | 76 | 98 | 116 | 108 | 108 | 134 |
| Total Liabilities | 233 | 260 | 261 | 238 | 240 | 261 | 311 | 320 | 336 | 376 |
| Fixed Assets | 60 | 71 | 70 | 71 | 69 | 67 | 76 | 80 | 87 | 94 |
| CWIP | 2 | 0 | 4 | 3 | 0 | 2 | 0 | 0 | 3 | 7 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 2 | 2 |
| Other Assets | 172 | 188 | 187 | 164 | 172 | 192 | 235 | 233 | 244 | 272 |
| Total Assets | 233 | 260 | 261 | 238 | 240 | 261 | 311 | 320 | 336 | 376 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 6 | 1 | 8 | 23 | 22 | 27 | -2 | 23 | 20 | 30 |
| Cash from Investing Activity | -8 | -4 | -8 | -5 | -6 | -9 | -22 | -19 | -15 | -21 |
| Cash from Financing Activity | -6 | 4 | 0 | -20 | -17 | -17 | 24 | -1 | -8 | -10 |
| Net Cash Flow | -8 | 1 | 0 | -2 | 0 | 0 | 0 | 3 | -2 | 0 |
| Free Cash Flow | -2 | -3 | -1 | 18 | 19 | 18 | -16 | 12 | 2 | 8 |
| CFO/OP | 52 | 11 | 57 | 465 | 91 | 117 | -4 | 88 | 75 | 95 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 99 | 111 | 105 | 106 | 98 | 98 | 113 | 107 | 111 | 110 |
| Inventory Days | 172 | 240 | 217 | 292 | 146 | 162 | 207 | 167 | 238 | 269 |
| Days Payable | 171 | 182 | 147 | 167 | 114 | 143 | 167 | 147 | 189 | 206 |
| Cash Conversion Cycle | 100 | 168 | 175 | 231 | 130 | 117 | 153 | 127 | 161 | 173 |
| Working Capital Days | 26 | 45 | 25 | -11 | 11 | 18 | 13 | 12 | 6 | 7 |
| ROCE % | 8 | 8 | 7 | 0 | 10 | 12 | 10 | 12 | 10 | 10 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 51.61% | 51.23% | 51.23% | 51.23% | 50.86% | 50.86% | 50.86% | 50.86% | 50.86% | 50.86% | 50.86% | 50.86% |
| FIIs | 0% | 0% | 0.13% | 0.13% | 0.13% | 0.14% | 0.14% | 0.15% | 0.22% | 0.14% | 0.14% | 0.15% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 32.19% | 32.63% | 32.15% | 32.36% | 33.15% | 32.57% | 32.49% | 32.41% | 32.97% | 33.02% | 32.84% | 32.86% |
| Others | 16.2% | 16.13% | 16.49% | 16.28% | 15.86% | 16.43% | 16.51% | 16.58% | 15.94% | 15.99% | 16.16% | 16.13% |
| No. of Shareholders | 15529 | 15060 | 14772 | 15014 | 16007 | 15667 | 15723 | 15826 | 15774 | 15520 | 15214 | 14974 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 13 / 5 / 1

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 94.77 | Buy |
| EMA (10) | 97.91 | Buy |
| SMA (20) | 89.96 | Buy |
| EMA (20) | 93.22 | Buy |
| SMA (50) | 87.82 | Buy |
| EMA (50) | 88.91 | Buy |
| SMA (100) | 85.31 | Buy |
| EMA (100) | 85.58 | Buy |
| SMA (200) | 78.76 | Buy |
| EMA (200) | 84.03 | Buy |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 70.15 | Sell |
| MACD (12,26,9) | 4.68 | Buy |
| Stochastic (14,3,3) | 72.13 | Neutral |
| ADX (14) | 31.72 | Buy |
| Williams %R (14) | -40.38 | Neutral |
| ATR (14) | 6.33 | High Volatility |
| ROC (12) | 28.54 | Buy |
| Stoch RSI (14) | 64.54 | Neutral |
| UO (7,14,28) | 49.04 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-10 | [Clarification Regarding Movement In Price](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=540f7d0d-94ea-496b-a967-31d39453f5ed.pdf) |
| 2026-09-07 | [Announcement under Regulation 30 (LODR)-Allotment](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f8f5b75a-23e8-4493-bb09-cfafbeb99591.pdf) |
| 2026-08-27 | [Intimation Of Record Date For Final Dividend](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8fa4219d-1cd5-47b9-ad07-e452cd3b4367.pdf) |
| 2026-08-26 | [Intimation - 39Th AGM Scheduled On 24Th September 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=92445c68-aa84-43d1-ac65-9e30c6bbbb53.pdf) |
| 2026-08-26 | [Bal Pharma Limited - Notice Of AGM](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d8403167-de73-46b3-ae67-1d326f417377.pdf) |
| 2026-08-26 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b6b3948f-fe90-4a7f-8961-22868b536771.pdf) |
| 2026-08-25 | [Clarification With Respect To Tentative Timeline For Utilization Of Net Proceeds Of Preferential Issue](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cb1bafb9-b9f5-4a1a-a65f-75d73fde8bfc.pdf) |
| 2026-08-13 | [Newspaper Publications - Unaudited Financial Results 30Th June 2026 And IEPF Notice](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e9c331a9-0e56-4830-ba9c-544ac8de40e9.pdf) |
| 2026-08-12 | [Board Meeting Outcome for Outcome Of Board Meeting Held On Wednesday August 12 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4b4e1b1f-00b6-4e26-a3eb-9e03a795ebb3.pdf) |
| 2026-08-10 | [Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=146b71b5-236e-4fa7-a9f1-af127702721e.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 8 Jan - Certificate under Reg 74(5) for quarter ended Dec 31, 2025; demat details furnished to BSE/NSE timely. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 8 Jan - Certificate under Reg 74(5) for quarter ended Dec 31, 2025; demat details furnished to BSE/NSE timely.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4cb2f185-360e-4a3e-b18a-681cc4b1643a.pdf) |
| 6 Apr - Confirmed Regulation 74(5) compliance for demat/remat details for quarter ended 31 March 2026. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 Apr - Confirmed Regulation 74(5) compliance for demat/remat details for quarter ended 31 March 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c6fed889-643b-4578-ad31-8922c8e62f77.pdf) |
| 3 Feb - Board meeting 11 Feb 2026 to approve unaudited results for quarter ended 31.12.2025; trading window closed 01.01–16.02.2026. | [Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended 31.12.2025. 3 Feb - Board meeting 11 Feb 2026 to approve unaudited results for quarter ended 31.12.2025; trading window closed 01.01–16.02.2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b00785f4-bc31-4ecc-b7a1-b9627296da90.pdf) |
| 29 Jan - Board approved unaudited results to Dec 31, 2025; standalone profit Rs1,169.20L, consolidated profit Rs574.03L | [Board Meeting Outcome for Outcome Of Board Meeting 29 Jan - Board approved unaudited results to Dec 31, 2025; standalone profit Rs1,169.20L, consolidated profit Rs574.03L](https://www.bseindia.com/xml-data/corpfiling/AttachHis/90fafd02-40cf-46bb-9612-700203da0bfe.pdf) |
| 29 Jan - Board approved Q3/9M unaudited results; ESS cost Rs1,130.95L and capital-reduction credit Rs575.47L. | [Outcome Of Board Meeting 29 Jan - Board approved Q3/9M unaudited results; ESS cost Rs1,130.95L and capital-reduction credit Rs575.47L.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d139ab64-9bd0-40a6-9976-8a409feabd79.pdf) |
| 21 Jan - Board meeting on Jan 29, 2026 to consider unaudited Q3 and nine-month results (Dec 31, 2025). | [Board Meeting Intimation for Considering And Taking On Record The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine Months Ended December 31, 2025. 21 Jan - Board meeting on Jan 29, 2026 to consider unaudited Q3 and nine-month results (Dec 31, 2025).](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0e9db205-5967-463d-ae92-2d5c36b931ec.pdf) |
| 2 Feb - Newspaper Advertisement-Results for the quarter and nine months ended December 31, 2025 | [Announcement under Regulation 30 (LODR)-Newspaper Publication 2 Feb - Newspaper Advertisement-Results for the quarter and nine months ended December 31, 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9c78c51c-641d-414d-b485-8849df21c0b6.pdf) |
| 16 Feb - Newspaper publication of Unaudited financial results for the quarter ended 31.12.2025. | [Announcement under Regulation 30 (LODR)-Newspaper Publication 16 Feb - Newspaper publication of Unaudited financial results for the quarter ended 31.12.2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2febd85a-699e-4d32-a54f-ef13b89be67d.pdf) |
| 11 Feb - Approved unaudited Q3 (31 Dec 2025) standalone and consolidated results; standalone net profit Rs194.62 lakh | [Board Meeting Outcome for Outcome Of The Board Meeting_ Standalone And Consolidated Financial Results For The Quarter Ended 31.12.2025. 11 Feb - Approved unaudited Q3 (31 Dec 2025) standalone and consolidated results; standalone net profit Rs194.62 lakh](https://www.bseindia.com/xml-data/corpfiling/AttachHis/09acae17-8acf-4cbc-ba43-7b14a1b04f2e.pdf) |
| 1 Mar - Prasun Banerjee resigned as Company Secretary, Compliance Officer and KMP effective March 1, 2026. | [Announcement under Regulation 30 (LODR)-Change in Management 1 Mar - Prasun Banerjee resigned as Company Secretary, Compliance Officer and KMP effective March 1, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/84360996-58f7-4cd9-a516-e6b52dfbe73b.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-12 | [Financial Result For The Quarter End 30Th June 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=51609111-70ae-45a3-840a-762cafd15d48.pdf) |
| 2026-05-27 | [Audited Financial Results-Standalone & Consolidated](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e318cd3b-af67-425f-8cae-ad89c16e0fa7.pdf) |
| 2026-02-11 | [Financial Results_31.12.2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=02b038d5-d692-43e3-926a-a3c2ae50863a.pdf) |
| 2025-11-12 | [Unaudited Financial Results For The Quarter Ended 30.09.2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=42dde0cc-3aff-405f-9f73-ecd86fafc6a5.pdf) |
| 2025-08-11 | [Unaudited Financial For The Quarter Ended 30.06.2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5da811ea-f250-4bf0-af0d-ec193eca38b5.pdf) |
| 2025-02-13 | [Un-Audited Standalone And Consolidated Financial Results For The Quarter Ended 30.09.2024.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6b9c1503-551d-46b8-aea6-dbc9b11688d0.pdf) |
| 2025-02-13 | [Standalone And Consolidated Financial Results For The Quarter Ended 31.12.2024.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=60694750-63e0-4871-8d03-a6ff0fe2011a.pdf) |
| 2024-11-14 | [Un-Audited Financial Results For The Quarter Ended 30.09.2024.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7826be06-be73-4b4d-9eef-504e2e17522a.pdf) |
| 2024-08-12 | [Unaudited Financial Results For The Quarter Ended 30.06.2024.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dc83ca16-90dd-4131-8584-b60159279e4b.pdf) |
| 2024-05-28 | [Audited Financial Results_31.03.2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=47ef817f-7f7a-4f05-b43e-9c591c375841.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Sep 2022 | [Concall - Sep 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a9ffac35-8f79-45a2-b88b-9a88e106e075.pdf) |
| Sep 2022 | [Concall - Sep 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4561806c-b55c-4560-aaec-2d919e9d735e.pdf) |
| Jun 2021 | [Concall - Jun 2021](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c9072612-584d-4bdd-8243-b13fa8052460.pdf) |
| Jul 2025 | [Concall - Jul 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e43c658f-652f-4cce-8f58-62943d00222f.pdf) |
| Feb 2023 | [Concall - Feb 2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=25d93a79-e12d-405b-bc0f-b6b1e2a02d68.pdf) |
| Feb 2023 | [Concall - Feb 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/25d93a79-e12d-405b-bc0f-b6b1e2a02d68.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Financial Year 2013 from nse](https://archives.nseindia.com/annual_reports/AR_472_TRF_2012_2013_12072013113904.zip) |
| from nse | [Annual Report 2011 from nse](https://archives.nseindia.com/annual_reports/AR_BALPHARMA_2010_2011_16122011102323.zip) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b01f19bc-25b0-4203-89d9-9935cdf36795.pdf) |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6693d643-1587-4af2-8997-a60ccda71819.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/70bcdb41-c60f-4a73-ad38-9ec852bae1bc.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/18a6ca48-3ebb-4d23-b56d-035b7e923b01.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3bdcbe9b-8fba-4ccb-963a-fb6e147278d2.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/524824/74728524824.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/505854/74161505854.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/524824/70382524824_30_09_21.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2022-09-23 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8c57bc7f-1788-4b09-bfe5-c2095e5c7f63.pdf) |
| 2022-09-07 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4561806c-b55c-4560-aaec-2d919e9d735e.pdf) |
| 2022-09-06 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a9ffac35-8f79-45a2-b88b-9a88e106e075.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:47:01.727Z.